These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15361777)

  • 1. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.
    White WB; Lacourciere Y
    J Hypertens; 2004 Oct; 22(10):2035-6; author reply 2036-8. PubMed ID: 15361777
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.
    Calvo C; Hermida RC; Ayala DE; Ruilope LM
    J Hypertens; 2004 Apr; 22(4):837-46. PubMed ID: 15126927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
    Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained antihypertensive activity of telmisartan compared with valsartan.
    Lacourcière Y; Krzesinski JM; White WB; Davidai G; Schumacher H
    Blood Press Monit; 2004 Aug; 9(4):203-10. PubMed ID: 15311147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
    Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
    Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.
    Bakris G
    J Clin Hypertens (Greenwich); 2002; 4(4 Suppl 1):26-31. PubMed ID: 12147926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours.
    Gosse P
    Vasc Health Risk Manag; 2006; 2(3):195-201. PubMed ID: 17326326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension.
    Zheng Z; Lin S; Shi H
    J Clin Hypertens (Greenwich); 2010 Jun; 12(6):414-21. PubMed ID: 20591086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
    Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
    Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
    [No Abstract]   [Full Text] [Related]  

  • 10. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
    Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
    Clin Cardiol; 2011 Apr; 34(4):261-5. PubMed ID: 21432858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction.
    Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
    Hypertens Res; 2013 Jul; 36(7):627-33. PubMed ID: 23344134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension.
    Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
    Oxid Med Cell Longev; 2010; 3(5):342-6. PubMed ID: 21150340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
    Volpe M
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1061-72. PubMed ID: 23030295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
    Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I
    Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
    Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
    Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.
    Khan AH; Imig JD
    Am J Hypertens; 2011 Jul; 24(7):816-21. PubMed ID: 21415842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.
    Takai S; Jin D; Kimura M; Kirimura K; Sakonjo H; Tanaka K; Miyazaki M
    Hypertens Res; 2007 Dec; 30(12):1231-7. PubMed ID: 18344629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.